Role of VIP and PACAP in islet function

被引:75
|
作者
Winzell, Maria Sorhede [1 ]
Ahren, Bo [1 ]
机构
[1] Lund Univ, Dept Clin Sci, Div Med, S-22184 Lund, Sweden
关键词
PACAP; VIP; islets; insulin secretion; receptor; parasympathetic;
D O I
10.1016/j.peptides.2007.04.024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are two closely related neuropeptides that are expressed in islets and in islet parasympathetic nerves. Both peptides bind to their common G-protein-coupled receptors, VPAC1 and VPAC2, and PACAP, in addition to the specific receptor PAC1, all three of which are expressed in islets. VIP and PACAP stimulate insulin secretion in a glucose-dependent manner and they both also stimulate glucagon secretion. This action is achieved through increased formation of cAMP after activation of adenylate cyclase and stimulation of extracellular calcium uptake. Deletion of PAC1 receptors or VPAC2 receptors results in glucose intolerance. These peptides may be of importance in mediating prandial insulin secretion and the glucagon response to hypoglycemia. Animal studies have also suggested that activation of the receptors, in particular VPAC2 receptors, may be used as a therapeutic approach for the treatment of type 2 diabetes. This review summarizes the current knowledge of the potential role of VIP and PACAP in islet function. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1805 / 1813
页数:9
相关论文
共 50 条
  • [1] Role of VIP and PACAP in the neural control of lower urinary tract function
    De Groat, William C.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2007, 33 (03) : 310 - 310
  • [2] Role of VIP/PACAP in primary headaches
    Edvinsson, Lars
    CEPHALALGIA, 2013, 33 (13) : 1070 - 1072
  • [3] Role of PACAP and VIP in astroglial functions
    Masmoudi-Kouki, Olfa
    Gandolfo, Pierrick
    Castel, Helene
    Leprince, Jerome
    Fournier, Alain
    Dejda, Agnieszka
    Vaudry, Hubert
    Tonon, Marie-Christine
    PEPTIDES, 2007, 28 (09) : 1753 - 1760
  • [4] A CHIMERIC VIP-PACAP ANALOG BUT NOT VIP PSEUDOPEPTIDES FUNCTION AS VIP RECEPTOR ANTAGONISTS
    FISHBEIN, VA
    COY, DH
    HOCART, SJ
    JIANG, NY
    MROZINSKI, JE
    MANTEY, SA
    JENSEN, RT
    PEPTIDES, 1994, 15 (01) : 95 - 100
  • [5] A CHIMERIC VIP-PACAP ANALOG BUT NOT VIP PSEUDOPEPTIDES FUNCTION AS VIP RECEPTOR ANTAGONISTS
    FISHBEYN, VA
    COY, DH
    JIANG, NZ
    JENSEN, RT
    GASTROENTEROLOGY, 1993, 104 (04) : A303 - A303
  • [6] Anti-inflammatory actions of VIP/PACAP - Role in endotoxemia
    Gomariz, R
    Leceta, J
    Martinez, C
    Abad, C
    Ganea, D
    Delgado, M
    VIP, PACAP, GLUCAGON, AND RELATED PEPTIDES, 2000, 921 : 284 - 288
  • [7] Modulatory role of PACAP and VIP on HIFs expression in lung adenocarcinoma
    D'Amico, Agata Grazia
    Maugeri, Grazia
    Rasa, Daniela Maria
    Reitano, Rita
    Saccone, Salvatore
    Federico, Concetta
    Magro, Gaetano
    D'Agata, Velia
    PEPTIDES, 2021, 146
  • [8] PACAP/VIP receptor characterization and regulation with cystitis in micturition pathways and functional role for pacap in urothelium
    Girard, B. M.
    Wolf-Johnston, A.
    Braas, K. M.
    Birder, L. A.
    May, V.
    Vizzard, M. A.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2007, 33 (03) : 347 - 347
  • [9] PACAP and VIP inhibit pyloric muscle through VIP/PACAP-preferring receptors
    Parkman, HP
    Pagano, AP
    Ryan, JP
    REGULATORY PEPTIDES, 1997, 71 (03) : 185 - 190
  • [10] Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors
    Gourlet, P
    Rathé, J
    De Neef, P
    Cnudde, J
    Vandermeers-Piret, MC
    Waelbroeck, M
    Robberecht, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 354 (01) : 105 - 111